Rituximab in relapsed or refractory hairy cell leukemia

Deborah A. Thomas, Susan O'Brien, Carlos Bueso-Ramos, Stefan Faderl, Michael J. Keating, Francis J. Giles, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved complete response (CR). The overall response rate was 80%. Eight patients (53%) achieved CR, 2 (13%) attained CR by hematologic parameters with residual marrow disease (1% to 5% marrow hairy cells), and 2 (13%) had a partial response. Of the 12 responders followed for a median of 32 months (range, 8 to 45+ months), 5 patients (42%) had progression of disease 8, 12, 18, 23, and 39 months from the start of therapy. Three patients failed to respond (after 4, 6, or 8 doses). Reductions in serum interleukin-2 receptor (sIL-2R) levels correlated with response. Toxicity was minimal, and no infectious episodes were observed. Rituximab has significant activity and minimal toxicity in HCL and warrants further study. Rituximab should be explored further in HCL with regard to eradication of minimal residual disease and in combination with nucleoside analogs.

Original languageEnglish (US)
Pages (from-to)3906-3911
Number of pages6
JournalBlood
Volume102
Issue number12
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Hairy Cell Leukemia
Refractory materials
Nucleosides
Toxicity
Bone Marrow
Interleukin-2 Receptors
Residual Neoplasm
Disease Progression
Monoclonal Antibodies
Safety
Rituximab
Serum
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Thomas, D. A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M. J., Giles, F. J., ... Kantarjian, H. M. (2003). Rituximab in relapsed or refractory hairy cell leukemia. Blood, 102(12), 3906-3911. https://doi.org/10.1182/blood-2003-02-0630

Rituximab in relapsed or refractory hairy cell leukemia. / Thomas, Deborah A.; O'Brien, Susan; Bueso-Ramos, Carlos; Faderl, Stefan; Keating, Michael J.; Giles, Francis J.; Cortes, Jorge; Kantarjian, Hagop M.

In: Blood, Vol. 102, No. 12, 01.12.2003, p. 3906-3911.

Research output: Contribution to journalArticle

Thomas, DA, O'Brien, S, Bueso-Ramos, C, Faderl, S, Keating, MJ, Giles, FJ, Cortes, J & Kantarjian, HM 2003, 'Rituximab in relapsed or refractory hairy cell leukemia', Blood, vol. 102, no. 12, pp. 3906-3911. https://doi.org/10.1182/blood-2003-02-0630
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 1;102(12):3906-3911. https://doi.org/10.1182/blood-2003-02-0630
Thomas, Deborah A. ; O'Brien, Susan ; Bueso-Ramos, Carlos ; Faderl, Stefan ; Keating, Michael J. ; Giles, Francis J. ; Cortes, Jorge ; Kantarjian, Hagop M. / Rituximab in relapsed or refractory hairy cell leukemia. In: Blood. 2003 ; Vol. 102, No. 12. pp. 3906-3911.
@article{4b75ea5b69c14eb4aa6618353afbdc05,
title = "Rituximab in relapsed or refractory hairy cell leukemia",
abstract = "The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved complete response (CR). The overall response rate was 80{\%}. Eight patients (53{\%}) achieved CR, 2 (13{\%}) attained CR by hematologic parameters with residual marrow disease (1{\%} to 5{\%} marrow hairy cells), and 2 (13{\%}) had a partial response. Of the 12 responders followed for a median of 32 months (range, 8 to 45+ months), 5 patients (42{\%}) had progression of disease 8, 12, 18, 23, and 39 months from the start of therapy. Three patients failed to respond (after 4, 6, or 8 doses). Reductions in serum interleukin-2 receptor (sIL-2R) levels correlated with response. Toxicity was minimal, and no infectious episodes were observed. Rituximab has significant activity and minimal toxicity in HCL and warrants further study. Rituximab should be explored further in HCL with regard to eradication of minimal residual disease and in combination with nucleoside analogs.",
author = "Thomas, {Deborah A.} and Susan O'Brien and Carlos Bueso-Ramos and Stefan Faderl and Keating, {Michael J.} and Giles, {Francis J.} and Jorge Cortes and Kantarjian, {Hagop M.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1182/blood-2003-02-0630",
language = "English (US)",
volume = "102",
pages = "3906--3911",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Rituximab in relapsed or refractory hairy cell leukemia

AU - Thomas, Deborah A.

AU - O'Brien, Susan

AU - Bueso-Ramos, Carlos

AU - Faderl, Stefan

AU - Keating, Michael J.

AU - Giles, Francis J.

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved complete response (CR). The overall response rate was 80%. Eight patients (53%) achieved CR, 2 (13%) attained CR by hematologic parameters with residual marrow disease (1% to 5% marrow hairy cells), and 2 (13%) had a partial response. Of the 12 responders followed for a median of 32 months (range, 8 to 45+ months), 5 patients (42%) had progression of disease 8, 12, 18, 23, and 39 months from the start of therapy. Three patients failed to respond (after 4, 6, or 8 doses). Reductions in serum interleukin-2 receptor (sIL-2R) levels correlated with response. Toxicity was minimal, and no infectious episodes were observed. Rituximab has significant activity and minimal toxicity in HCL and warrants further study. Rituximab should be explored further in HCL with regard to eradication of minimal residual disease and in combination with nucleoside analogs.

AB - The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved complete response (CR). The overall response rate was 80%. Eight patients (53%) achieved CR, 2 (13%) attained CR by hematologic parameters with residual marrow disease (1% to 5% marrow hairy cells), and 2 (13%) had a partial response. Of the 12 responders followed for a median of 32 months (range, 8 to 45+ months), 5 patients (42%) had progression of disease 8, 12, 18, 23, and 39 months from the start of therapy. Three patients failed to respond (after 4, 6, or 8 doses). Reductions in serum interleukin-2 receptor (sIL-2R) levels correlated with response. Toxicity was minimal, and no infectious episodes were observed. Rituximab has significant activity and minimal toxicity in HCL and warrants further study. Rituximab should be explored further in HCL with regard to eradication of minimal residual disease and in combination with nucleoside analogs.

UR - http://www.scopus.com/inward/record.url?scp=0345689335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345689335&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-02-0630

DO - 10.1182/blood-2003-02-0630

M3 - Article

C2 - 12816862

AN - SCOPUS:0345689335

VL - 102

SP - 3906

EP - 3911

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -